The study findings indicated that quercetin, a heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1) inhibitor, is highly effective in resensitising enzalutamide-resistant prostate cancer cells to enzalutamide. Here, HNRNPA1 is linked to prostate carcinoma.